Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir

Dolutegravir is a second-generation integrase strand transfer inhibitor (INSTI) currently under review by the US Food and Drug Administration for marketing approval. The in vitro, protein-adjusted 90 % inhibitory concentration (IC 90 ) of dolutegravir for wild-type virus is 0.064 μg/ml, and it retai...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Clinical pharmacokinetics Ročník 52; číslo 11; s. 981 - 994
Hlavní autoři:	Cottrell, Mackenzie L., Hadzic, Tanja, Kashuba, Angela D. M.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Cham Springer International Publishing 01.11.2013 Adis International Springer Nature B.V
Témata:	Biological and medical sciences Drug Interactions General pharmacology Heterocyclic Compounds, 3-Ring - administration & dosage Heterocyclic Compounds, 3-Ring - pharmacokinetics HIV Integrase Inhibitors - administration & dosage HIV Integrase Inhibitors - pharmacokinetics Humans Internal Medicine Medical sciences Medicine Medicine & Public Health Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions Pharmacology. Drug treatments Pharmacology/Toxicology Pharmacotherapy Review Article Atazanavir Telaprevir Efavirenz Tenofovir Disoproxil Fumarate Raltegravir Human Pharmacokinetic pharmacodynamic relationship Drug interaction Integrase inhibitor Dolutegravir
ISSN:	0312-5963, 1179-1926, 1179-1926
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	Dolutegravir is a second-generation integrase strand transfer inhibitor (INSTI) currently under review by the US Food and Drug Administration for marketing approval. The in vitro, protein-adjusted 90 % inhibitory concentration (IC 90 ) of dolutegravir for wild-type virus is 0.064 μg/ml, and it retains in vitro anti-HIV 1 activity across a broad range of viral phenotypes that are known to confer resistance to the currently marketed INSTIs, raltegravir and elvitegravir. Dolutegravir has a terminal elimination half-life of 13–14 h and maintains concentrations over the in vitro, protein-adjusted IC 90 for more than 30 h following a single dose. Additionally, dolutegravir has low inter-subject variability compared with raltegravir and elvitegravir. A plasma exposure–response relationship has been well described, with antiviral activity strongly correlating with trough concentrations. Phase III trials have assessed the antiviral activity of dolutegravir compared with efavirenz and raltegravir in antiretroviral (ARV)-naive patients and found that dolutegravir achieved more rapid and sustained virologic suppression in both instances. Additionally, studies of dolutegravir activity in patients with known INSTI-resistant mutations have been favourable, indicating that dolutegravir retains activity in a variety of INSTI-resistant phenotypes. Much like currently marketed INSTIs, dolutegravir is very well tolerated. Because dolutegravir inhibits the renal transporter organic cation transporter 2, reduced tubular secretion of creatinine leads to non-progressive increases in serum creatinine. These serum creatinine increases have not been associated with a decreased glomerular filtration rate or progressive renal impairment. Dolutegravir’s major and minor metabolic pathways are uridine diphosphate glucuronosyltransferase 1A1 and cytochrome P450 (CYP)-3A4, respectively, and it neither induces nor inhibits CYP isoenzymes. Thus dolutegravir has a modest drug interaction profile. However, antacids significantly decrease dolutegravir plasma exposure and should be separated by 2 h before, or 6 h after, a dolutegravir dose. In summary, dolutegravir is the first of the second-generation INSTIs and exhibits a predictable pharmacokinetic profile and a well-defined exposure–response relationship. Dolutegravir retains activity despite the presence of some class-resistant mutations and achieves rapid and sustained virologic suppression in ARV-naive and ARV-experienced patients. Clinically, dolutegravir is poised to become a commonly used component of antiretroviral regimens.
AbstractList	Dolutegravir is a second generation integrase strand transfer inhibitor (INSTI) currently under review by the US FDA for marketing approval. Dolutegravir’s in vitro, protein adjusted 90% inhibitory concentration (IC90) for wild-type virus is 0.064 μg/ml, and it retains in vitro anti-HIV 1 activity across a broad range of viral phenotypes known to confer resistance to the currently marketed INSTIs, raltegravir and elvitegravir. Dolutegravir has a half-life (t½) of 13 to 14 hours and maintains concentrations over the in vitro, protein adjusted IC90 for more than 30 hours following a single dose. Additionally, dolutegravir has comparatively low intersubject variability compared to raltegravir and elvitegravir. A plasma exposure-response relationship has been well described, with antiviral activity strongly correlating to trough concentration (Ctrough) values. Phase III trials have assessed the antiviral activity of dolutegravir compared with efavirenz and raltegravir in antiretroviral (ARV)-naïve patients and found dolutegravir to achieve more rapid and sustained virologic suppression in both instances. Additionally, studies of dolutegravir activity in patients with known INSTI-resistant mutations have been favorable, indicating that dolutegravir retains activity in a variety of INSTI resistant phenotypes. Much like currently marketed INSTIs, dolutegravir is very well tolerated. Because dolutegravir inhibits the renal transporter, organic cation transporter (OCT) 2, reduced tubular secretion of creatinine leads to non-progressive increases in serum creatinine. These serum creatinine increases have not been associated with decreased glomerular filtration rate or progressive renal impairment. Dolutegravir’s major and minor metabolic pathways are UDP glucuronosyltransferase (UGT)1A1 and cytochrome (CYP)3A4, respectively, and it neither induces nor inhibits CYP isozymes. Thus dolutegravir has a modest drug interaction profile. However, antacids significantly decrease dolutegravir plasma exposure and should be separated by 2 hours before, or 6 hours after, a dolutegravir dose. In summary, dolutegravir is the first of the second generation INSTIs, which exhibits a predictable pharmacokinetic profile and a well-defined exposure-response relationship. Dolutegravir retains activity despite the presence of some class resistant mutations and achieves rapid and sustained virologic suppression in ARV-naïve and -experienced patients. Clinically dolutegravir is poised to become a commonly used component of antiretroviral regimens. Dolutegravir is a second-generation integrase strand transfer inhibitor (INSTI) currently under review by the US Food and Drug Administration for marketing approval. The in vitro, protein-adjusted 90 % inhibitory concentration (IC90) of dolutegravir for wild-type virus is 0.064 μg/ml, and it retains in vitro anti-HIV 1 activity across a broad range of viral phenotypes that are known to confer resistance to the currently marketed INSTIs, raltegravir and elvitegravir. Dolutegravir has a terminal elimination half-life of 13-14 h and maintains concentrations over the in vitro, protein-adjusted IC90 for more than 30 h following a single dose. Additionally, dolutegravir has low inter-subject variability compared with raltegravir and elvitegravir. A plasma exposure-response relationship has been well described, with antiviral activity strongly correlating with trough concentrations. Phase III trials have assessed the antiviral activity of dolutegravir compared with efavirenz and raltegravir in antiretroviral (ARV)-naive patients and found that dolutegravir achieved more rapid and sustained virologic suppression in both instances. Additionally, studies of dolutegravir activity in patients with known INSTI-resistant mutations have been favourable, indicating that dolutegravir retains activity in a variety of INSTI-resistant phenotypes. Much like currently marketed INSTIs, dolutegravir is very well tolerated. Because dolutegravir inhibits the renal transporter organic cation transporter 2, reduced tubular secretion of creatinine leads to non-progressive increases in serum creatinine. These serum creatinine increases have not been associated with a decreased glomerular filtration rate or progressive renal impairment. Dolutegravir's major and minor metabolic pathways are uridine diphosphate glucuronosyltransferase 1A1 and cytochrome P450 (CYP)-3A4, respectively, and it neither induces nor inhibits CYP isoenzymes. Thus dolutegravir has a modest drug interaction profile. However, antacids significantly decrease dolutegravir plasma exposure and should be separated by 2 h before, or 6 h after, a dolutegravir dose. In summary, dolutegravir is the first of the second-generation INSTIs and exhibits a predictable pharmacokinetic profile and a well-defined exposure-response relationship. Dolutegravir retains activity despite the presence of some class-resistant mutations and achieves rapid and sustained virologic suppression in ARV-naive and ARV-experienced patients. Clinically, dolutegravir is poised to become a commonly used component of antiretroviral regimens. Dolutegravir is a second-generation integrase strand transfer inhibitor (INSTI) currently under review by the US Food and Drug Administration for marketing approval. The in vitro, protein-adjusted 90 % inhibitory concentration (IC90) of dolutegravir for wild-type virus is 0.064 μg/ml, and it retains in vitro anti-HIV 1 activity across a broad range of viral phenotypes that are known to confer resistance to the currently marketed INSTIs, raltegravir and elvitegravir. Dolutegravir has a terminal elimination half-life of 13-14 h and maintains concentrations over the in vitro, protein-adjusted IC90 for more than 30 h following a single dose. Additionally, dolutegravir has low inter-subject variability compared with raltegravir and elvitegravir. A plasma exposure-response relationship has been well described, with antiviral activity strongly correlating with trough concentrations. Phase III trials have assessed the antiviral activity of dolutegravir compared with efavirenz and raltegravir in antiretroviral (ARV)-naive patients and found that dolutegravir achieved more rapid and sustained virologic suppression in both instances. Additionally, studies of dolutegravir activity in patients with known INSTI-resistant mutations have been favourable, indicating that dolutegravir retains activity in a variety of INSTI-resistant phenotypes. Much like currently marketed INSTIs, dolutegravir is very well tolerated. Because dolutegravir inhibits the renal transporter organic cation transporter 2, reduced tubular secretion of creatinine leads to non-progressive increases in serum creatinine. These serum creatinine increases have not been associated with a decreased glomerular filtration rate or progressive renal impairment. Dolutegravir's major and minor metabolic pathways are uridine diphosphate glucuronosyltransferase 1A1 and cytochrome P450 (CYP)-3A4, respectively, and it neither induces nor inhibits CYP isoenzymes. Thus dolutegravir has a modest drug interaction profile. However, antacids significantly decrease dolutegravir plasma exposure and should be separated by 2 h before, or 6 h after, a dolutegravir dose. In summary, dolutegravir is the first of the second-generation INSTIs and exhibits a predictable pharmacokinetic profile and a well-defined exposure-response relationship. Dolutegravir retains activity despite the presence of some class-resistant mutations and achieves rapid and sustained virologic suppression in ARV-naive and ARV-experienced patients. Clinically, dolutegravir is poised to become a commonly used component of antiretroviral regimens.Dolutegravir is a second-generation integrase strand transfer inhibitor (INSTI) currently under review by the US Food and Drug Administration for marketing approval. The in vitro, protein-adjusted 90 % inhibitory concentration (IC90) of dolutegravir for wild-type virus is 0.064 μg/ml, and it retains in vitro anti-HIV 1 activity across a broad range of viral phenotypes that are known to confer resistance to the currently marketed INSTIs, raltegravir and elvitegravir. Dolutegravir has a terminal elimination half-life of 13-14 h and maintains concentrations over the in vitro, protein-adjusted IC90 for more than 30 h following a single dose. Additionally, dolutegravir has low inter-subject variability compared with raltegravir and elvitegravir. A plasma exposure-response relationship has been well described, with antiviral activity strongly correlating with trough concentrations. Phase III trials have assessed the antiviral activity of dolutegravir compared with efavirenz and raltegravir in antiretroviral (ARV)-naive patients and found that dolutegravir achieved more rapid and sustained virologic suppression in both instances. Additionally, studies of dolutegravir activity in patients with known INSTI-resistant mutations have been favourable, indicating that dolutegravir retains activity in a variety of INSTI-resistant phenotypes. Much like currently marketed INSTIs, dolutegravir is very well tolerated. Because dolutegravir inhibits the renal transporter organic cation transporter 2, reduced tubular secretion of creatinine leads to non-progressive increases in serum creatinine. These serum creatinine increases have not been associated with a decreased glomerular filtration rate or progressive renal impairment. Dolutegravir's major and minor metabolic pathways are uridine diphosphate glucuronosyltransferase 1A1 and cytochrome P450 (CYP)-3A4, respectively, and it neither induces nor inhibits CYP isoenzymes. Thus dolutegravir has a modest drug interaction profile. However, antacids significantly decrease dolutegravir plasma exposure and should be separated by 2 h before, or 6 h after, a dolutegravir dose. In summary, dolutegravir is the first of the second-generation INSTIs and exhibits a predictable pharmacokinetic profile and a well-defined exposure-response relationship. Dolutegravir retains activity despite the presence of some class-resistant mutations and achieves rapid and sustained virologic suppression in ARV-naive and ARV-experienced patients. Clinically, dolutegravir is poised to become a commonly used component of antiretroviral regimens. Dolutegravir is a second-generation integrase strand transfer inhibitor (INSTI) currently under review by the US Food and Drug Administration for marketing approval. The in vitro, protein-adjusted 90 % inhibitory concentration (IC 90 ) of dolutegravir for wild-type virus is 0.064 μg/ml, and it retains in vitro anti-HIV 1 activity across a broad range of viral phenotypes that are known to confer resistance to the currently marketed INSTIs, raltegravir and elvitegravir. Dolutegravir has a terminal elimination half-life of 13–14 h and maintains concentrations over the in vitro, protein-adjusted IC 90 for more than 30 h following a single dose. Additionally, dolutegravir has low inter-subject variability compared with raltegravir and elvitegravir. A plasma exposure–response relationship has been well described, with antiviral activity strongly correlating with trough concentrations. Phase III trials have assessed the antiviral activity of dolutegravir compared with efavirenz and raltegravir in antiretroviral (ARV)-naive patients and found that dolutegravir achieved more rapid and sustained virologic suppression in both instances. Additionally, studies of dolutegravir activity in patients with known INSTI-resistant mutations have been favourable, indicating that dolutegravir retains activity in a variety of INSTI-resistant phenotypes. Much like currently marketed INSTIs, dolutegravir is very well tolerated. Because dolutegravir inhibits the renal transporter organic cation transporter 2, reduced tubular secretion of creatinine leads to non-progressive increases in serum creatinine. These serum creatinine increases have not been associated with a decreased glomerular filtration rate or progressive renal impairment. Dolutegravir’s major and minor metabolic pathways are uridine diphosphate glucuronosyltransferase 1A1 and cytochrome P450 (CYP)-3A4, respectively, and it neither induces nor inhibits CYP isoenzymes. Thus dolutegravir has a modest drug interaction profile. However, antacids significantly decrease dolutegravir plasma exposure and should be separated by 2 h before, or 6 h after, a dolutegravir dose. In summary, dolutegravir is the first of the second-generation INSTIs and exhibits a predictable pharmacokinetic profile and a well-defined exposure–response relationship. Dolutegravir retains activity despite the presence of some class-resistant mutations and achieves rapid and sustained virologic suppression in ARV-naive and ARV-experienced patients. Clinically, dolutegravir is poised to become a commonly used component of antiretroviral regimens.
Author	Hadzic, Tanja Cottrell, Mackenzie L. Kashuba, Angela D. M.
Author_xml	– sequence: 1 givenname: Mackenzie L. surname: Cottrell fullname: Cottrell, Mackenzie L. organization: Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill – sequence: 2 givenname: Tanja surname: Hadzic fullname: Hadzic, Tanja organization: Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill – sequence: 3 givenname: Angela D. M. surname: Kashuba fullname: Kashuba, Angela D. M. email: akashuba@unc.edu organization: Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill
BackLink	http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27885483$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/23824675$$D View this record in MEDLINE/PubMed
BookMark	eNp9kktv1DAUhS1URKeFH8AGRUJILAj4kfixqYSmPCpVogtYWzeOPeOS2MVOKvXf4zDDUCrBypbvd67v0T0n6CjEYBF6TvBbgrF4lxtMOa0xYTXGitX0EVoRIlRNFOVHaIUZoXWrODtGJzlfY4wlxfgJOqZM0oaLdoXCevDBGxiqqy2kEUz87oOdvHlzeOjvAozeVBD66jzNm_oiTDaBmXwM1VWKzg-2iq6atrZaSpsEebltfeenmKrzOMy_Xm99eooeOxiyfbY_T9G3jx--rj_Xl18-XazfX9am5XyqFVAO0lgpmeoZE9IS5tpWOiH7RgAQ1XcSt8a0nXXAgRsLPXOs74gCaS07RWe7vjdzN9re2DAlGPRN8iOkOx3B678rwW_1Jt5qVtoKQkuD1_sGKf6YbZ706LOxwwDBxjlr0jQNU7TFsqAvH6DXcU6h2CsU57jBUolCvbg_0WGU36sowKs9ALnswyUIxuc_nJCybSQrHNlxJsWck3UHhGC9xELvYqFLLPQSC724EQ80xk-wLLCY98N_lXSnzOWXsLHpnrl_in4CqrDNlA
CODEN	CPKNDH
CitedBy_id	crossref_primary_10_1016_j_curtheres_2014_05_002 crossref_primary_10_1371_journal_ppat_1011676 crossref_primary_10_1097_FTD_0000000000001169 crossref_primary_10_1136_bmjopen_2021_054019 crossref_primary_10_1093_infdis_jiw406 crossref_primary_10_1080_14787210_2018_1544491 crossref_primary_10_1093_jac_dky093 crossref_primary_10_3892_wasj_2025_385 crossref_primary_10_1016_S2352_3018_17_30095_4 crossref_primary_10_1097_INF_0000000000004859 crossref_primary_10_1016_j_ajoc_2024_102170 crossref_primary_10_1002_cpdd_740 crossref_primary_10_1016_j_heliyon_2024_e27219 crossref_primary_10_1093_ofid_ofad542 crossref_primary_10_1128_AAC_01310_18 crossref_primary_10_1517_14740338_2015_973845 crossref_primary_10_3389_fmed_2024_1329922 crossref_primary_10_3390_ijms24076267 crossref_primary_10_1002_jppr_1346 crossref_primary_10_1111_hiv_12468 crossref_primary_10_1186_s40780_017_0093_8 crossref_primary_10_1007_s40121_024_01085_z crossref_primary_10_1002_jcph_2225 crossref_primary_10_1080_17425255_2017_1277203 crossref_primary_10_1038_s41467_023_35928_z crossref_primary_10_3390_cancers13174366 crossref_primary_10_1093_jac_dkv358 crossref_primary_10_1007_s40262_016_0458_4 crossref_primary_10_1016_j_jconrel_2023_10_006 crossref_primary_10_1136_bmj_n1380 crossref_primary_10_1016_j_jddst_2022_103802 crossref_primary_10_1016_j_jpha_2016_05_008 crossref_primary_10_1177_23259582221111077 crossref_primary_10_1002_jia2_25656 crossref_primary_10_1007_s40121_021_00522_7 crossref_primary_10_1097_QAD_0000000000001394 crossref_primary_10_3390_pharmaceutics13091325 crossref_primary_10_1186_s12981_015_0054_y crossref_primary_10_1080_17425255_2021_1915284 crossref_primary_10_1177_0956462418816785 crossref_primary_10_3390_cancers15123191 crossref_primary_10_1002_jia2_25885 crossref_primary_10_1097_QAD_0000000000002256 crossref_primary_10_1080_1547691X_2022_2142705 crossref_primary_10_1136_bmjopen_2019_035246 crossref_primary_10_1093_cid_ciae278 crossref_primary_10_1038_s43705_022_00186_5 crossref_primary_10_1111_cts_70035 crossref_primary_10_1371_journal_pone_0310239 crossref_primary_10_1002_cpt_1748 crossref_primary_10_1016_j_jfluchem_2020_109639 crossref_primary_10_3109_03639045_2015_1115869 crossref_primary_10_1128_aac_01297_22 crossref_primary_10_3390_v16121953 crossref_primary_10_1007_s12035_018_1273_8 crossref_primary_10_1016_j_ejps_2019_105137 crossref_primary_10_1111_hiv_12710 crossref_primary_10_1371_journal_pone_0220323 crossref_primary_10_1093_cid_ciz926 crossref_primary_10_3851_IMP3236 crossref_primary_10_1016_j_heliyon_2023_e22541 crossref_primary_10_3851_IMP3119 crossref_primary_10_1136_sextrans_2020_054821 crossref_primary_10_1016_j_ces_2023_119453 crossref_primary_10_1080_14787210_2020_1729742 crossref_primary_10_1093_jac_dkaa234 crossref_primary_10_1097_QAD_0000000000002950 crossref_primary_10_1016_j_jpba_2020_113119 crossref_primary_10_1097_QAI_0000000000003402 crossref_primary_10_1097_QAD_0000000000001191 crossref_primary_10_3389_fimmu_2025_1532318 crossref_primary_10_1002_cpdd_996 crossref_primary_10_1097_MD_0000000000031100 crossref_primary_10_1177_2040206615595318 crossref_primary_10_3389_fnmol_2024_1459877 crossref_primary_10_1002_bio_70080 crossref_primary_10_1097_QAD_0000000000003929 crossref_primary_10_1517_14656566_2014_868883 crossref_primary_10_1093_jac_dkz478 crossref_primary_10_1016_j_jpba_2019_113057 crossref_primary_10_1007_s40266_021_00894_y crossref_primary_10_1002_psp4_13244 crossref_primary_10_1097_FTD_0000000000000290 crossref_primary_10_1186_s12879_021_06991_y crossref_primary_10_1093_cid_ciz256 crossref_primary_10_1016_j_jcv_2018_11_002 crossref_primary_10_1093_jac_dkae147 crossref_primary_10_1371_journal_pmed_1002895 crossref_primary_10_1002_jia2_25970 crossref_primary_10_1186_s12879_024_09202_6 crossref_primary_10_1586_14787210_2014_907525 crossref_primary_10_1007_s43440_023_00515_y crossref_primary_10_7759_cureus_56487 crossref_primary_10_1016_S2213_2600_14_70017_7 crossref_primary_10_1097_FTD_0000000000000286 crossref_primary_10_1128_AAC_01316_17 crossref_primary_10_11604_pamj_2024_47_137_40726 crossref_primary_10_1093_jac_dkv425 crossref_primary_10_1093_ofid_ofac107 crossref_primary_10_1097_QAD_0000000000001401 crossref_primary_10_1177_1060028019830788 crossref_primary_10_1002_psp4_13251 crossref_primary_10_1093_jac_dky384 crossref_primary_10_1093_jpids_piy139 crossref_primary_10_1002_cpt_3482 crossref_primary_10_1016_j_diamond_2021_108332 crossref_primary_10_1080_14622416_2024_2441104 crossref_primary_10_1111_hiv_13136 crossref_primary_10_1093_jac_dkad043 crossref_primary_10_1096_fj_202402677RR crossref_primary_10_1093_cid_ciad265 crossref_primary_10_1016_j_jiac_2017_12_022 crossref_primary_10_1093_jac_dkw186 crossref_primary_10_1097_QAD_0000000000004007 crossref_primary_10_1002_cpt_3727 crossref_primary_10_1186_s12879_017_2755_4 crossref_primary_10_1177_1060028013513558 crossref_primary_10_1186_s41100_020_00282_z crossref_primary_10_1093_jac_dkz217 crossref_primary_10_1097_QAD_0000000000003706 crossref_primary_10_3389_fphar_2023_1053814 crossref_primary_10_1016_j_pharmthera_2023_108459 crossref_primary_10_1007_s11904_023_00645_1 crossref_primary_10_1016_S0140_6736_17_33095_7 crossref_primary_10_3390_v16071162 crossref_primary_10_1097_QAI_0000000000003281 crossref_primary_10_1093_ndt_gfw064 crossref_primary_10_1093_cid_civ124 crossref_primary_10_1007_s40265_014_0256_y crossref_primary_10_1007_s10928_022_09822_y crossref_primary_10_1038_s41598_020_69102_y crossref_primary_10_1016_j_ijantimicag_2021_106343 crossref_primary_10_1186_s12889_020_09991_w crossref_primary_10_1111_bcp_12428 crossref_primary_10_1097_QAD_0000000000003843 crossref_primary_10_1080_19390211_2020_1846658 crossref_primary_10_3390_genes16080971 crossref_primary_10_36303_SAPJ_0135 crossref_primary_10_1186_s12977_017_0359_0 crossref_primary_10_1016_j_bioorg_2025_108273 crossref_primary_10_1093_jac_dkx495 crossref_primary_10_7705_biomedica_v38i4_3885 crossref_primary_10_1002_bdd_2045 crossref_primary_10_1093_toxsci_kfab112 crossref_primary_10_1093_jac_dkz558 crossref_primary_10_1097_QAD_0000000000001438 crossref_primary_10_1016_S2352_3018_18_30093_6 crossref_primary_10_1371_journal_pone_0293162 crossref_primary_10_1177_0956462419848962 crossref_primary_10_1097_FTD_0000000000000929 crossref_primary_10_1371_journal_pmed_1003421 crossref_primary_10_1038_s41598_025_02688_3 crossref_primary_10_1093_ofid_ofad361 crossref_primary_10_2147_IDR_S451346 crossref_primary_10_1080_14656566_2017_1417984 crossref_primary_10_1007_s11481_017_9761_6 crossref_primary_10_1155_2022_3510277 crossref_primary_10_1097_QAD_0000000000001447 crossref_primary_10_1093_cid_ciaa1861 crossref_primary_10_1097_IPC_0000000000000490 crossref_primary_10_1016_j_cca_2017_12_034 crossref_primary_10_2174_1574885514666181217125550 crossref_primary_10_1128_AAC_01643_21 crossref_primary_10_1016_j_bjid_2024_104463 crossref_primary_10_1371_journal_pone_0210476 crossref_primary_10_1080_17425255_2017_1361929 crossref_primary_10_1016_j_lfs_2022_120948 crossref_primary_10_1097_QCO_0000000000000106 crossref_primary_10_1007_s40262_018_0684_z crossref_primary_10_1177_2040622314530461 crossref_primary_10_1016_S2352_3018_23_00228_X crossref_primary_10_3389_fphar_2023_1118580 crossref_primary_10_1007_s13318_017_0438_6 crossref_primary_10_1093_jac_dkx461 crossref_primary_10_1097_QCO_0000000000000453 crossref_primary_10_1089_aid_2023_0046 crossref_primary_10_1093_jac_dkx105 crossref_primary_10_7196_SAMJ_2022_v112i10_16596 crossref_primary_10_1136_bmjopen_2024_085819 crossref_primary_10_1016_j_ijid_2022_01_001 crossref_primary_10_2215_CJN_02240218 crossref_primary_10_1097_FPC_0000000000000562 crossref_primary_10_1080_17512433_2024_2308664 crossref_primary_10_1093_jac_dkad100 crossref_primary_10_1208_s12248_020_00498_1 crossref_primary_10_1007_s11481_020_09904_z crossref_primary_10_1038_s41467_018_06490_w crossref_primary_10_1016_S0140_6736_24_00048_5 crossref_primary_10_1128_aac_00215_22 crossref_primary_10_1016_j_jgar_2019_08_010 crossref_primary_10_1080_00498254_2025_2453983 crossref_primary_10_1128_AAC_03131_15 crossref_primary_10_1177_09564624251352064 crossref_primary_10_1007_s40265_015_0446_2 crossref_primary_10_1093_jac_dkz506 crossref_primary_10_1128_aac_00430_23 crossref_primary_10_1016_j_jmii_2025_08_024 crossref_primary_10_1093_cid_ciac585 crossref_primary_10_1016_j_pharmthera_2016_01_009 crossref_primary_10_1093_jac_dkab022 crossref_primary_10_1097_QAD_0000000000004071 crossref_primary_10_1016_j_ijantimicag_2019_04_009 crossref_primary_10_1016_j_jiph_2020_06_016
Cites_doi	10.1097/QAI.0b013e3181ae69c5 10.1124/jpet.103.049601 10.1128/AAC.06170-11 10.1097/QAI.0b013e31827a0d71 10.1128/AAC.05739-11 10.1097/01.qai.0000233308.82860.2f 10.3851/IMP1652 10.1128/AAC.00241-10 10.1177/096032719101000209 10.1111/j.1365-2125.2012.04440.x 10.1097/QAI.0b013e31826bfd02 10.1093/infdis/jis750 10.1016/S0140-6736(12)61853-4 10.1097/COH.0b013e3282f82c1b 10.1124/dmd.112.048918 10.1093/infdis/jir636 10.2165/00003088-200645070-00003 10.1097/QAI.0b013e318276cda9 10.1124/mol.111.073189 10.1124/dmd.109.027854 10.1093/jac/dkr139 10.1128/AAC.00842-09 10.1128/AAC.00157-11 10.1128/AAC.01209-10 10.1128/AAC.00073-11 10.1097/QAD.0b013e32834a1dd9 10.1097/COH.0b013e328356e91c 10.1016/S1473-3099(11)70290-0 10.1177/0091270010371113 10.1002/j.1875-9114.2012.01033.x 10.1038/sj.clpt.6100342 10.1097/QAI.0b013e3181e67909 10.1111/j.1365-2125.2011.03947.x 10.7448/IAS.15.6.18112
ContentType	Journal Article
Copyright	Springer International Publishing Switzerland 2013 2014 INIST-CNRS Copyright Wolters Kluwer Health Adis International Nov 2013
Copyright_xml	– notice: Springer International Publishing Switzerland 2013 – notice: 2014 INIST-CNRS – notice: Copyright Wolters Kluwer Health Adis International Nov 2013
DBID	AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 4T- 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM
DOI	10.1007/s40262-013-0093-2
DatabaseName	CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Docstoc Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland AUTh Library subscriptions: ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete ProQuest Health & Medical Research Collection Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) Docstoc Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	ProQuest One Academic Middle East (New) MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine Pharmacy, Therapeutics, & Pharmacology
EISSN	1179-1926
EndPage	994
ExternalDocumentID	PMC3805712 3149985891 23824675 27885483 10_1007_s40262_013_0093_2
Genre	Journal Article Review Research Support, N.I.H., Extramural
GrantInformation_xml	– fundername: NIAID NIH HHS grantid: U01 AI095031 – fundername: NIGMS NIH HHS grantid: T32 GM086330 – fundername: NIAID NIH HHS grantid: P30 AI050410 – fundername: PHS HHS grantid: U01 AU095031 – fundername: NIAID NIH HHS grantid: P30 AI50410 – fundername: National Institute of Allergy and Infectious Diseases Extramural Activities : NIAID grantid: P30 AI050410 \|\| AI – fundername: National Institute of Allergy and Infectious Diseases Extramural Activities : NIAID grantid: U01 AI095031 \|\| AI
GroupedDBID	--- -5G -BR -EM .GJ .XZ 0R~ 0VX 199 29B 2JY 34G 36B 39C 3V. 4.4 406 53G 5GY 5RE 6I2 6J9 6PF 7X7 88E 8FI 8FJ 8R4 8R5 8UJ 95. AAAUJ AABHQ AACDK AADNT AAIAL AAIKX AAJKR AAKAS AANZL AARHV AASML AATNV AAWTL AAYQN AAYTO AAYZH ABAKF ABDZT ABFTV ABIPD ABJNI ABJOX ABKCH ABKMS ABKTR ABOCM ABPLI ABTKH ABTMW ABUWG ABWHX ABXPI ACAOD ACCOQ ACCUX ACDTI ACGFO ACGFS ACMJI ACMLO ACOKC ACPIV ACREN ACZOJ ADBBV ADFRT ADFZG ADHHG ADJJI ADQRH ADRFC ADURQ ADYOE ADZCM ADZKW AEBTG AEFQL AEJHL AEJRE AEMSY AENEX AEOHA AEPYU AESKC AEVLU AEXYK AEYRQ AFALF AFBBN AFFNX AFKRA AFWTZ AFZKB AGAYW AGDGC AGQEE AGQMX AGRTI AHIZS AHMBA AHSBF AIAKS AIGIU AILAN AIZAD AJRNO ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMXSW AMYLF ASPBG AVWKF AWSVR AXYYD AZFZN A~4 BENPR BGNMA BPHCQ BVXVI BYPQX CAG CCPQU COF CS3 DCUDU DNIVK DPUIP DU5 EBLON EBS EJD EMOBN ESX F5P F8P FERAY FIGPU FLLZZ FNLPD FSGXE FYUFA HF~ HMCUK IAO IEA IHR IMOTQ INH INR ITC IWAJR J-C JZLTJ LGEZI LLZTM LOTEE M1P M4Y NADUK NQJWS NU0 NXXTH OAC OPC OVD P2P PQQKQ PROAC PSQYO Q2X ROL RSV RZALA SISQX SJYHP SNPRN SNX SOHCF SOJ SPKJE SRMVM SSLCW TEORI TSG U5U U9L UAX UG4 UKHRP UNMZH UTJUX VDBLX VFIZW W48 WAF YQY Z0Y Z7U ZGI ZMTXR ZXP ~JE AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC AEZWR AFDZB AFFHD AFHIU AFOHR AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT PJZUB PPXIY IQODW CGR CUY CVF ECM EIF NPM 4T- 7XB 8FK K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO 5PM
ID	FETCH-LOGICAL-c566t-9a26a8ce8839d3378e13f558f78d47aa19db805cc5befa6a6cead3f3db19a8ee3
IEDL.DBID	RSV
ISICitedReferencesCount	234
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000325961500004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0312-5963 1179-1926
IngestDate	Tue Nov 04 01:57:11 EST 2025 Thu Oct 02 10:32:29 EDT 2025 Fri Nov 07 23:28:41 EST 2025 Mon Jul 21 06:05:49 EDT 2025 Mon Jul 21 09:15:29 EDT 2025 Tue Nov 18 21:30:44 EST 2025 Sat Nov 29 02:48:25 EST 2025 Fri Feb 21 02:45:16 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	11
Keywords	Atazanavir Telaprevir Efavirenz Tenofovir Disoproxil Fumarate Raltegravir Human Pharmacokinetic pharmacodynamic relationship Drug interaction Integrase inhibitor Dolutegravir
Language	English
License	CC BY 4.0
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c566t-9a26a8ce8839d3378e13f558f78d47aa19db805cc5befa6a6cead3f3db19a8ee3
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-General Information-1 content type line 14 ObjectType-Feature-3 ObjectType-Article-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
OpenAccessLink	http://dx.doi.org/10.1007/s40262-013-0093-2
PMID	23824675
PQID	1466040897
PQPubID	32335
PageCount	14
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_3805712 proquest_miscellaneous_1444392508 proquest_journals_1466040897 pubmed_primary_23824675 pascalfrancis_primary_27885483 crossref_primary_10_1007_s40262_013_0093_2 crossref_citationtrail_10_1007_s40262_013_0093_2 springer_journals_10_1007_s40262_013_0093_2
PublicationCentury	2000
PublicationDate	2013-11-01
PublicationDateYYYYMMDD	2013-11-01
PublicationDate_xml	– month: 11 year: 2013 text: 2013-11-01 day: 01
PublicationDecade	2010
PublicationPlace	Cham
PublicationPlace_xml	– name: Cham – name: Auckland – name: Switzerland
PublicationTitle	Clinical pharmacokinetics
PublicationTitleAbbrev	Clin Pharmacokinet
PublicationTitleAlternate	Clin Pharmacokinet
PublicationYear	2013
Publisher	Springer International Publishing Adis International Springer Nature B.V
Publisher_xml	– name: Springer International Publishing – name: Adis International – name: Springer Nature B.V
References	Kobayashi, Yoshinaga, Seki (CR7) 2011; 55 Cao, Hendrix (CR27) 2008; 83 CR36 CR34 CR33 Calcagno, Bonora, D’Avolio (CR26) 2010; 54 CR32 Eron, Clotet, Durant (CR18) 2013; 207 CR31 Ward, Gorski, Jones (CR42) 2003; 306 CR30 Raffi, Rachlis, Stellbrink (CR19) 2013; 381 Song, Borland, Min (CR47) 2011; 55 CR2 Dooley, Sayre, Borland (CR53) 2013; 62 CR4 CR3 Song, Borland, Chen (CR48) 2011; 72 Hare, Smith, Metifiot (CR6) 2011; 80 Reese, Savina, Generaux (CR15) 2013; 41 Min, Sloan, DeJesus (CR12) 2011; 25 Song, Borland, Chen (CR16) 2012; 56 Chen, Min, Peppercorn (CR39) 2012; 32 Nichols, Mills, Grossberg (CR35) 2012; 15 CR45 CR44 CR43 CR40 Patel, Song, Borland (CR52) 2011; 66 Adams, Greener, Kashuba (CR1) 2012; 7 Song, Min, Borland (CR41) 2010; 55 Min, Song, Borland (CR11) 2010; 54 King, Acosta (CR50) 2006; 45 Antoniou, Hasan, Loutfy (CR25) 2013; 62 CR13 CR57 CR55 CR54 CR51 Canducci, Ceresola, Boeri (CR10) 2011; 204 van Lunzen, Maggiolo, Arribas (CR17) 2012; 12 Garrido, Villacian, Zahonero (CR5) 2012; 56 Underwood, Johns, Sato (CR9) 2012; 61 DeJesus, Berger, Markowitz (CR14) 2006; 43 Dumond, Patterson, Pecha (CR23) 2009; 51 Tolson, Li, Eddington (CR56) 2009; 37 CR29 Salas Herrera, Pearson, Turner (CR24) 1991; 10 CR28 Hightower, Wang, Deanda (CR8) 2011; 55 CR22 CR21 CR20 van Luin, Kuks, Burger (CR37) 2008; 3 Kakuda, Scholler-Gyure, Hoetelmans (CR46) 2010; 15 Song, Min, Borland (CR49) 2011; 51 Koteff, Borland, Chen (CR38) 2013; 75 KE Dooley (93_CR53) 2013; 62 TN Kakuda (93_CR46) 2010; 15 JL Adams (93_CR1) 2012; 7 93_CR44 93_CR45 C Garrido (93_CR5) 2012; 56 93_CR40 93_CR43 I Song (93_CR48) 2011; 72 G Nichols (93_CR35) 2012; 15 J van Lunzen (93_CR17) 2012; 12 MR Underwood (93_CR9) 2012; 61 B Ward (93_CR42) 2003; 306 J Koteff (93_CR38) 2013; 75 I Song (93_CR41) 2010; 55 93_CR33 93_CR34 E DeJesus (93_CR14) 2006; 43 M Kobayashi (93_CR7) 2011; 55 93_CR36 93_CR30 93_CR31 93_CR32 93_CR4 I Song (93_CR47) 2011; 55 93_CR3 93_CR2 AH Tolson (93_CR56) 2009; 37 JR King (93_CR50) 2006; 45 JB Dumond (93_CR23) 2009; 51 S Chen (93_CR39) 2012; 32 MJ Reese (93_CR15) 2013; 41 M van Luin (93_CR37) 2008; 3 YJ Cao (93_CR27) 2008; 83 KE Hightower (93_CR8) 2011; 55 F Canducci (93_CR10) 2011; 204 93_CR22 S Hare (93_CR6) 2011; 80 JJ Eron (93_CR18) 2013; 207 93_CR20 T Antoniou (93_CR25) 2013; 62 93_CR21 P Patel (93_CR52) 2011; 66 F Raffi (93_CR19) 2013; 381 93_CR28 93_CR29 S Min (93_CR11) 2010; 54 IG Salas Herrera (93_CR24) 1991; 10 A Calcagno (93_CR26) 2010; 54 S Min (93_CR12) 2011; 25 93_CR55 93_CR13 93_CR57 93_CR51 I Song (93_CR16) 2012; 56 I Song (93_CR49) 2011; 51 93_CR54 20585260 - J Acquir Immune Defic Syndr. 2010 Nov;55(3):365-7 19520773 - Drug Metab Dispos. 2009 Sep;37(9):1887-94 21555764 - Antimicrob Agents Chemother. 2011 Jul;55(7):3517-21 21984737 - J Infect Dis. 2011 Dec 1;204(11):1811-5 21115794 - Antimicrob Agents Chemother. 2011 Feb;55(2):813-21 1675106 - Hum Exp Toxicol. 1991 Mar;10(2):137-9 23225901 - J Infect Dis. 2013 Mar 1;207(5):740-8 16936557 - J Acquir Immune Defic Syndr. 2006 Sep;43(1):1-5 22422361 - Pharmacotherapy. 2012 Apr;32(4):333-9 20834094 - Antivir Ther. 2010;15(6):817-29 23306000 - Lancet. 2013 Mar 2;381(9868):735-43 21493648 - J Antimicrob Chemother. 2011 Jul;66(7):1567-72 22905856 - Br J Clin Pharmacol. 2013 Apr;75(4):990-6 22878423 - J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):297-301 19546811 - J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):546-53 20489027 - J Clin Pharmacol. 2011 Feb;51(2):237-42 21719464 - Mol Pharmacol. 2011 Oct;80(4):565-72 17786163 - Clin Pharmacol Ther. 2008 Mar;83(3):401-12 23979733 - Antimicrob Agents Chemother. 2013 Nov;57(11):5472-7 22018760 - Lancet Infect Dis. 2012 Feb;12(2):111-8 19372977 - Curr Opin HIV AIDS. 2008 May;3(3):266-71 21342217 - Br J Clin Pharmacol. 2011 Jul;72(1):103-8 21807982 - Antimicrob Agents Chemother. 2011 Oct;55(10):4552-9 20308369 - Antimicrob Agents Chemother. 2010 Jun;54(6):2744-5 21716073 - AIDS. 2011 Sep 10;25(14):1737-45 12676886 - J Pharmacol Exp Ther. 2003 Jul;306(1):287-300 22789987 - Curr Opin HIV AIDS. 2012 Sep;7(5):390-400 23328092 - J Acquir Immune Defic Syndr. 2013 Feb 1;62(2):e58-60 16802849 - Clin Pharmacokinet. 2006;45(7):665-82 23075918 - J Acquir Immune Defic Syndr. 2013 Jan 1;62(1):21-7 23132334 - Drug Metab Dispos. 2013 Feb;41(2):353-61 22183173 - Antimicrob Agents Chemother. 2012 Mar;56(3):1627-9 22450969 - Antimicrob Agents Chemother. 2012 Jun;56(6):2873-8 19884365 - Antimicrob Agents Chemother. 2010 Jan;54(1):254-8
References_xml	– ident: CR45 – ident: CR22 – volume: 51 start-page: 546 issue: 5 year: 2009 end-page: 553 ident: CR23 article-title: Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0b013e3181ae69c5 – volume: 306 start-page: 287 issue: 1 year: 2003 end-page: 300 ident: CR42 article-title: The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity publication-title: J Pharmacol Exp Therap doi: 10.1124/jpet.103.049601 – volume: 56 start-page: 2873 issue: 6 year: 2012 end-page: 2878 ident: CR5 article-title: Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.06170-11 – ident: CR4 – volume: 62 start-page: e58 issue: 2 year: 2013 end-page: e60 ident: CR25 article-title: Pharmacokinetics of maraviroc, raltegravir, darunavir, and etravirine in the semen of HIV-infected men publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0b013e31827a0d71 – volume: 56 start-page: 1627 issue: 3 year: 2012 end-page: 1629 ident: CR16 article-title: Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.05739-11 – ident: CR51 – volume: 43 start-page: 1 issue: 1 year: 2006 end-page: 5 ident: CR14 article-title: Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients publication-title: J Acquir Immune Defic Syndr doi: 10.1097/01.qai.0000233308.82860.2f – volume: 15 start-page: 817 issue: 6 year: 2010 end-page: 829 ident: CR46 article-title: Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine publication-title: Antivir Ther doi: 10.3851/IMP1652 – volume: 54 start-page: 2744 issue: 6 year: 2010 end-page: 2745 ident: CR26 article-title: Raltegravir penetration in seminal plasma of healthy volunteers publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00241-10 – ident: CR29 – ident: CR54 – ident: CR21 – volume: 10 start-page: 137 issue: 2 year: 1991 end-page: 139 ident: CR24 article-title: Quantitation of albumin and alpha-1-acid glycoprotein in human cervical mucus publication-title: Hum Exp Toxicol doi: 10.1177/096032719101000209 – volume: 75 start-page: 990 issue: 4 year: 2013 end-page: 996 ident: CR38 article-title: A phase 1 study to evaluate dolutegravir’s effect on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.2012.04440.x – ident: CR57 – volume: 61 start-page: 297 issue: 3 year: 2012 end-page: 301 ident: CR9 article-title: The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0b013e31826bfd02 – ident: CR32 – volume: 207 start-page: 740 year: 2013 end-page: 748 ident: CR18 article-title: Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING study publication-title: J Infect Dis doi: 10.1093/infdis/jis750 – ident: CR36 – volume: 381 start-page: 735 issue: 9868 year: 2013 end-page: 743 ident: CR19 article-title: Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study publication-title: Lancet doi: 10.1016/S0140-6736(12)61853-4 – volume: 3 start-page: 266 issue: 3 year: 2008 end-page: 271 ident: CR37 article-title: Use of therapeutic drug monitoring in HIV disease publication-title: Curr Opin HIV AIDS doi: 10.1097/COH.0b013e3282f82c1b – volume: 41 start-page: 353 issue: 2 year: 2013 end-page: 361 ident: CR15 article-title: In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor publication-title: Drug Metab Dispos doi: 10.1124/dmd.112.048918 – volume: 204 start-page: 1811 issue: 11 year: 2011 end-page: 1815 ident: CR10 article-title: Cross-resistance profile of the novel integrase inhibitor dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir publication-title: J Infect Dis doi: 10.1093/infdis/jir636 – volume: 45 start-page: 665 issue: 7 year: 2006 end-page: 682 ident: CR50 article-title: Tipranavir: a novel nonpeptidic protease inhibitor of HIV publication-title: Clin Pharmacokinet doi: 10.2165/00003088-200645070-00003 – volume: 62 start-page: 21 issue: 1 year: 2013 end-page: 27 ident: CR53 article-title: Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0b013e318276cda9 – volume: 80 start-page: 565 issue: 4 year: 2011 end-page: 572 ident: CR6 article-title: Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572) publication-title: Mol Pharmacol doi: 10.1124/mol.111.073189 – ident: CR43 – ident: CR2 – volume: 37 start-page: 1887 issue: 9 year: 2009 end-page: 1894 ident: CR56 article-title: Methadone induces the expression of hepatic drug-metabolizing enzymes through the activation of pregnane X receptor and constitutive androstane receptor publication-title: Drug Metab Dispos doi: 10.1124/dmd.109.027854 – ident: CR30 – volume: 66 start-page: 1567 issue: 7 year: 2011 end-page: 1572 ident: CR52 article-title: Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkr139 – volume: 54 start-page: 254 issue: 1 year: 2010 end-page: 258 ident: CR11 article-title: Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00842-09 – volume: 55 start-page: 4552 issue: 10 year: 2011 end-page: 4559 ident: CR8 article-title: Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00157-11 – ident: CR33 – volume: 55 start-page: 813 issue: 2 year: 2011 end-page: 821 ident: CR7 article-title: In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01209-10 – volume: 55 start-page: 3517 issue: 7 year: 2011 end-page: 3521 ident: CR47 article-title: Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00073-11 – volume: 25 start-page: 1737 issue: 14 year: 2011 end-page: 1745 ident: CR12 article-title: Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults publication-title: AIDS doi: 10.1097/QAD.0b013e32834a1dd9 – volume: 7 start-page: 390 issue: 5 year: 2012 end-page: 400 ident: CR1 article-title: Pharmacology of HIV integrase inhibitors publication-title: Curr Opin HIV AIDS doi: 10.1097/COH.0b013e328356e91c – volume: 12 start-page: 111 issue: 2 year: 2012 end-page: 118 ident: CR17 article-title: Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(11)70290-0 – ident: CR40 – ident: CR44 – volume: 51 start-page: 237 issue: 2 year: 2011 end-page: 242 ident: CR49 article-title: The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants publication-title: J Clin Pharmacol doi: 10.1177/0091270010371113 – ident: CR3 – volume: 32 start-page: 333 issue: 4 year: 2012 end-page: 339 ident: CR39 article-title: Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization publication-title: Pharmacotherapy doi: 10.1002/j.1875-9114.2012.01033.x – volume: 83 start-page: 401 issue: 3 year: 2008 end-page: 412 ident: CR27 article-title: Male genital tract pharmacology: developments in quantitative methods to better understand a complex peripheral compartment publication-title: Clin Pharmacol Ther doi: 10.1038/sj.clpt.6100342 – ident: CR31 – ident: CR13 – ident: CR34 – ident: CR55 – volume: 55 start-page: 365 issue: 3 year: 2010 end-page: 367 ident: CR41 article-title: Lack of interaction between the HIV integrase inhibitor S/GSK1349572 and tenofovir in healthy subjects publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0b013e3181e67909 – volume: 15 start-page: 18112 issue: Suppl 4 year: 2012 ident: CR35 article-title: Antiviral activity of dolutegravir in subjects with failure on an integrase inhibitor-based regimen: week 24 phase 3 results from VIKING-3 publication-title: J Int AIDS Soc – ident: CR28 – volume: 72 start-page: 103 issue: 1 year: 2011 end-page: 108 ident: CR48 article-title: Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572 publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.2011.03947.x – ident: CR20 – volume: 62 start-page: 21 issue: 1 year: 2013 ident: 93_CR53 publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0b013e318276cda9 – ident: 93_CR55 – ident: 93_CR32 – volume: 10 start-page: 137 issue: 2 year: 1991 ident: 93_CR24 publication-title: Hum Exp Toxicol doi: 10.1177/096032719101000209 – ident: 93_CR51 – volume: 55 start-page: 3517 issue: 7 year: 2011 ident: 93_CR47 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00073-11 – volume: 55 start-page: 4552 issue: 10 year: 2011 ident: 93_CR8 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00157-11 – volume: 25 start-page: 1737 issue: 14 year: 2011 ident: 93_CR12 publication-title: AIDS doi: 10.1097/QAD.0b013e32834a1dd9 – volume: 381 start-page: 735 issue: 9868 year: 2013 ident: 93_CR19 publication-title: Lancet doi: 10.1016/S0140-6736(12)61853-4 – volume: 306 start-page: 287 issue: 1 year: 2003 ident: 93_CR42 publication-title: J Pharmacol Exp Therap doi: 10.1124/jpet.103.049601 – volume: 15 start-page: 817 issue: 6 year: 2010 ident: 93_CR46 publication-title: Antivir Ther doi: 10.3851/IMP1652 – ident: 93_CR4 – volume: 207 start-page: 740 year: 2013 ident: 93_CR18 publication-title: J Infect Dis doi: 10.1093/infdis/jis750 – volume: 54 start-page: 2744 issue: 6 year: 2010 ident: 93_CR26 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00241-10 – volume: 61 start-page: 297 issue: 3 year: 2012 ident: 93_CR9 publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0b013e31826bfd02 – volume: 83 start-page: 401 issue: 3 year: 2008 ident: 93_CR27 publication-title: Clin Pharmacol Ther doi: 10.1038/sj.clpt.6100342 – volume: 7 start-page: 390 issue: 5 year: 2012 ident: 93_CR1 publication-title: Curr Opin HIV AIDS doi: 10.1097/COH.0b013e328356e91c – volume: 75 start-page: 990 issue: 4 year: 2013 ident: 93_CR38 publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.2012.04440.x – ident: 93_CR31 – volume: 66 start-page: 1567 issue: 7 year: 2011 ident: 93_CR52 publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkr139 – volume: 80 start-page: 565 issue: 4 year: 2011 ident: 93_CR6 publication-title: Mol Pharmacol doi: 10.1124/mol.111.073189 – ident: 93_CR20 – ident: 93_CR13 – ident: 93_CR45 – volume: 55 start-page: 365 issue: 3 year: 2010 ident: 93_CR41 publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0b013e3181e67909 – volume: 43 start-page: 1 issue: 1 year: 2006 ident: 93_CR14 publication-title: J Acquir Immune Defic Syndr doi: 10.1097/01.qai.0000233308.82860.2f – volume: 51 start-page: 237 issue: 2 year: 2011 ident: 93_CR49 publication-title: J Clin Pharmacol doi: 10.1177/0091270010371113 – volume: 72 start-page: 103 issue: 1 year: 2011 ident: 93_CR48 publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.2011.03947.x – volume: 45 start-page: 665 issue: 7 year: 2006 ident: 93_CR50 publication-title: Clin Pharmacokinet doi: 10.2165/00003088-200645070-00003 – ident: 93_CR28 – ident: 93_CR30 – volume: 37 start-page: 1887 issue: 9 year: 2009 ident: 93_CR56 publication-title: Drug Metab Dispos doi: 10.1124/dmd.109.027854 – volume: 55 start-page: 813 issue: 2 year: 2011 ident: 93_CR7 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01209-10 – volume: 204 start-page: 1811 issue: 11 year: 2011 ident: 93_CR10 publication-title: J Infect Dis doi: 10.1093/infdis/jir636 – volume: 54 start-page: 254 issue: 1 year: 2010 ident: 93_CR11 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00842-09 – ident: 93_CR34 – ident: 93_CR44 – ident: 93_CR21 – ident: 93_CR40 – volume: 12 start-page: 111 issue: 2 year: 2012 ident: 93_CR17 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(11)70290-0 – volume: 56 start-page: 1627 issue: 3 year: 2012 ident: 93_CR16 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.05739-11 – ident: 93_CR2 – volume: 32 start-page: 333 issue: 4 year: 2012 ident: 93_CR39 publication-title: Pharmacotherapy doi: 10.1002/j.1875-9114.2012.01033.x – ident: 93_CR29 – ident: 93_CR54 – volume: 3 start-page: 266 issue: 3 year: 2008 ident: 93_CR37 publication-title: Curr Opin HIV AIDS doi: 10.1097/COH.0b013e3282f82c1b – volume: 56 start-page: 2873 issue: 6 year: 2012 ident: 93_CR5 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.06170-11 – ident: 93_CR33 – volume: 15 start-page: 18112 issue: Suppl 4 year: 2012 ident: 93_CR35 publication-title: J Int AIDS Soc doi: 10.7448/IAS.15.6.18112 – volume: 62 start-page: e58 issue: 2 year: 2013 ident: 93_CR25 publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0b013e31827a0d71 – ident: 93_CR36 – ident: 93_CR43 – volume: 51 start-page: 546 issue: 5 year: 2009 ident: 93_CR23 publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0b013e3181ae69c5 – ident: 93_CR22 – ident: 93_CR57 – ident: 93_CR3 – volume: 41 start-page: 353 issue: 2 year: 2013 ident: 93_CR15 publication-title: Drug Metab Dispos doi: 10.1124/dmd.112.048918 – reference: 23306000 - Lancet. 2013 Mar 2;381(9868):735-43 – reference: 23225901 - J Infect Dis. 2013 Mar 1;207(5):740-8 – reference: 16936557 - J Acquir Immune Defic Syndr. 2006 Sep;43(1):1-5 – reference: 22450969 - Antimicrob Agents Chemother. 2012 Jun;56(6):2873-8 – reference: 20834094 - Antivir Ther. 2010;15(6):817-29 – reference: 22878423 - J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):297-301 – reference: 22183173 - Antimicrob Agents Chemother. 2012 Mar;56(3):1627-9 – reference: 21984737 - J Infect Dis. 2011 Dec 1;204(11):1811-5 – reference: 17786163 - Clin Pharmacol Ther. 2008 Mar;83(3):401-12 – reference: 21807982 - Antimicrob Agents Chemother. 2011 Oct;55(10):4552-9 – reference: 22905856 - Br J Clin Pharmacol. 2013 Apr;75(4):990-6 – reference: 22422361 - Pharmacotherapy. 2012 Apr;32(4):333-9 – reference: 20489027 - J Clin Pharmacol. 2011 Feb;51(2):237-42 – reference: 19884365 - Antimicrob Agents Chemother. 2010 Jan;54(1):254-8 – reference: 23075918 - J Acquir Immune Defic Syndr. 2013 Jan 1;62(1):21-7 – reference: 19546811 - J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):546-53 – reference: 23328092 - J Acquir Immune Defic Syndr. 2013 Feb 1;62(2):e58-60 – reference: 21115794 - Antimicrob Agents Chemother. 2011 Feb;55(2):813-21 – reference: 21716073 - AIDS. 2011 Sep 10;25(14):1737-45 – reference: 21493648 - J Antimicrob Chemother. 2011 Jul;66(7):1567-72 – reference: 21342217 - Br J Clin Pharmacol. 2011 Jul;72(1):103-8 – reference: 12676886 - J Pharmacol Exp Ther. 2003 Jul;306(1):287-300 – reference: 21555764 - Antimicrob Agents Chemother. 2011 Jul;55(7):3517-21 – reference: 1675106 - Hum Exp Toxicol. 1991 Mar;10(2):137-9 – reference: 23132334 - Drug Metab Dispos. 2013 Feb;41(2):353-61 – reference: 23979733 - Antimicrob Agents Chemother. 2013 Nov;57(11):5472-7 – reference: 22018760 - Lancet Infect Dis. 2012 Feb;12(2):111-8 – reference: 20585260 - J Acquir Immune Defic Syndr. 2010 Nov;55(3):365-7 – reference: 16802849 - Clin Pharmacokinet. 2006;45(7):665-82 – reference: 19372977 - Curr Opin HIV AIDS. 2008 May;3(3):266-71 – reference: 20308369 - Antimicrob Agents Chemother. 2010 Jun;54(6):2744-5 – reference: 22789987 - Curr Opin HIV AIDS. 2012 Sep;7(5):390-400 – reference: 19520773 - Drug Metab Dispos. 2009 Sep;37(9):1887-94 – reference: 21719464 - Mol Pharmacol. 2011 Oct;80(4):565-72
SSID	ssj0008200
Score	2.5419078
SecondaryResourceType	review_article
Snippet	Dolutegravir is a second-generation integrase strand transfer inhibitor (INSTI) currently under review by the US Food and Drug Administration for marketing... Dolutegravir is a second generation integrase strand transfer inhibitor (INSTI) currently under review by the US FDA for marketing approval. Dolutegravir’s in...
SourceID	pubmedcentral proquest pubmed pascalfrancis crossref springer
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	981
SubjectTerms	Biological and medical sciences Drug Interactions General pharmacology Heterocyclic Compounds, 3-Ring - administration & dosage Heterocyclic Compounds, 3-Ring - pharmacokinetics HIV Integrase Inhibitors - administration & dosage HIV Integrase Inhibitors - pharmacokinetics Humans Internal Medicine Medical sciences Medicine Medicine & Public Health Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions Pharmacology. Drug treatments Pharmacology/Toxicology Pharmacotherapy Review Article
SummonAdditionalLinks	– databaseName: Health & Medical Collection dbid: 7X7 link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5B4YCEeBfSlspIqAfYqEmcxM4JIUoFEqr2UKS9RY7ttBEluyS7lfbfMxMnWZZHL9wi24nszOsb2zMD8Foh6jCk_VKJ4haHkfYl2kk_ztA4odtsjAsU_iLOzuRslk37Dbe2v1Y56MROUZu5pj3yY5ToFBlOZuLd4odPVaPodLUvoXEb7lDZbOJzMRsdLrJugQvUQYcLOW041aTQOfSbUrqUwH1y6v1oyy7dX6gWf1Hpalv8DXz-eYfyt4PUzj6dPvzflT2CBz0yZe8dKz2GW7Z-AkdTl9p6PWHnm0itdsKO2HST9Hr9FOo-wejV2P4N8SuOnYwNZl2r75VmqjbspFld-N1upAusYFNXO5zNS4aQlH12WSxaerqsClQ7DTshKaHW66p5Bl9PP55_-OT3tRx8jYBx6WcqSpXUViIgM5wLaUNeJokshTSxUCrMTCGDROuksKVKVaqRxXnJTRFmSlrLd2Gnntf2BTCdJMIksdU2jWKtUmllgiAvMDYMitJoD4KBkrnuE51TvY2rfEzR3BE_R-LnRPw88uDN-MrCZfm4afDhFnuMb0RCSnQAuQcHA6HzXiO0-YbKHrwau1GW6YBG1Xa-ojEx4kMEpdKD5469Nh_nMkKjlnggthhvHEB5wrd76uqyyxfO8ceKEOf9dmDRX6b1r1Xu3byIfbgXkfB0UZkHsLNsVvYl3NXXy6ptDjsx_Ane4DrU priority: 102 providerName: ProQuest
Title	Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir
URI	https://link.springer.com/article/10.1007/s40262-013-0093-2 https://www.ncbi.nlm.nih.gov/pubmed/23824675 https://www.proquest.com/docview/1466040897 https://www.proquest.com/docview/1444392508 https://pubmed.ncbi.nlm.nih.gov/PMC3805712
Volume	52
WOSCitedRecordID	wos000325961500004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1179-1926 dateEnd: 20241209 omitProxy: false ssIdentifier: ssj0008200 issn: 0312-5963 databaseCode: 7X7 dateStart: 20070601 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1179-1926 dateEnd: 20241209 omitProxy: false ssIdentifier: ssj0008200 issn: 0312-5963 databaseCode: BENPR dateStart: 20070601 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1179-1926 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0008200 issn: 0312-5963 databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9RAEB-0FRHEj6o1Wo8VpA96gSSbZCePalsU9DhqlXsLm92NPVpyJbkr9L93NpvkPK2CvoSwmSzJZHY-Mju_AXglyevQVvulSMstDiPlI9lJP87IOFHYrLUrFP4kJhOczbJpV8fd9Lvd-5Rkq6mHYjeKdFK7jYD7Ngz3Se9uk7VD26_h-Mu3Qf2SSQtcdQ5FWSRefSrzuik2jNHdC9kQX0rX0OI6j_P3jZO_ZE9bo3R0_79e5wHc63xQ9tYJzUO4YaoduP25y7LvwP7U4VlfjdnJujyrGbN9Nl0jXV89gqpDFT0fxs9oAqIdDwPadbxnstLsoF5999tfkK6agk1dw3C2KBn5oeyjg65o7NnpvCBdU7MDuzTs6OW8fgxfjw5P3n_wuwYOviIvcelnMkolKoPkhWnOBZqQl0mCpUAdCynDTBcYJEolhSllKlNFcs1Lroswk2gMfwJb1aIyT4GpJBE6iY0yaRQrmaLBhDy7QJswKEqtPAj6L5mrDt3cNtk4zwdc5pbhOTE8twzPIw9eD7dcOGiPvxGPNsRjuCMSiBT1cQ_2ennJOzXQ2LgqJS2JmfDg5XCZFrDNysjKLFaWJiankDxR9GDXidd6co4RWbLEA7EheAOBBQffvFLNT1uQcE6MFSE995te_H56rD-95bN_on4OdyIrv21l5h5sLeuVeQG31OVy3tQjuClmoj3iCLbfHU6mx6N2pf4AJL42xA
linkProvider	Springer Nature
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VgkQlxPsRKMVI0ANsRN52DgghlqqrLqs9LNLeUsd22oiSXZLdov1T_EbGcZJlefTWA7fIcaLY-WbmG9szA_CCI-uQWvtFDMUtcD1hM7STdhCjcUK3WUoTKDykoxGbTuPxFvxoY2H0scpWJ9aKWs6EXiN_gxIdIeBYTN_Nv9m6apTeXW1LaBhYHKnVd3TZqreDPv7fl5538HHy4dBuqgrYAqnLwo65F3EmFENqIH2fMuX6WRiyjDIZUM7dWKbMCYUIU5XxiEcCJ9vPfJm6MWdK-fjeK3AV9TjVzh6ddg6etqaOCQxCBw-R3e6i6lA99NMifQjCt_Uigu1t2MEbc17hL8lMLY2_kd0_z2z-tnFb28ODW__bTN6Gmw3zJu-NqNyBLVXchf2xSd296pHJOhKt6pF9Ml4n9V7dg6JJoHrWtX9Bfo59e12DXBX8ay4ILyTpl8sTu15tNYEjZGxqo5NZRpByk4HJ0lHpq9M8RbVakr7WArr1PC_vw-dLmYsHsF3MCvUIiAhDKsNACRV5geARUyxEEutI5TppJoUFToucRDSJ3HU9kbOkS0Fdgy1BsCUabIlnwavukbnJYnJR570NOHZPeJQxdHB9C3ZbYCWNxquSNaoseN7dRl2lN6B4oWZL3SdA_oukm1nw0MB5_XKfeWi0QwvoBtC7DjoP-uadIj-t86H7OLHUxe9-3YrEL5_1r1E-vngQz-D64eTTMBkORkdPYMfTgltHoO7C9qJcqqdwTZwv8qrcq1UAgePLlpSfY-ebMA
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3db9MwED-NDqFJiO9BYAwjwR6g0ZpPOw8IAV1FtamK0JD2FhzbYREjLUk71H-Nv45znKSUj73tgbfIcaLY-d3d72zfHcAzjqxDau0XMhQ333GFzdBO2n6ExgndZilNoPARnUzYyUkUb8CPNhZGH6tsdWKtqOVU6DXyfZToEAHHIrqfNcci4uHo9eybrStI6Z3WtpyGgcihWn5H9616NR7iv37uuqOD43fv7abCgC2QxsztiLshZ0IxpAnS8yhTjpcFAcsokz7l3IlkygaBEEGqMh7yUODEe5knUyfiTCkP33sFNimSDL8Hm28PJvGHzg6gbR2YMCF09xDn7Z6qDtxDry3URyI8Wy8p2O6aVbw-4xX-oMxU1vgb9f3zBOdv27i1dRzd_J_n9RbcaDg5eWOE6DZsqOIO7MUmqfeyT45XMWpVn-yReJXue3kXiia16lnX_gWZO_btdw1yWfCvuSC8kGRYLj7b9TqsCSkhsamaTqYZQTJOxiZ_R6WvTvMUFW5Jhlo_6NbzvLwHHy9lLrahV0wL9QCICAIqA18JFbq-4CFTLEB6O5DKGaSZFBYMWhQloknxriuNnCVdcuoaeAkCL9HAS1wLXnSPzEx-k4s6765Bs3vCpYyh6-tZsNOCLGl0YZWsEGbB0-42ajG9NcULNV3oPj4yY6TjzIL7Btqrl3vMRXMeWEDXQN910BnS1-8U-WmdKd3DiaUOfvfLVjx--ax_jfLhxYN4AtdQQJKj8eTwEWy5Wobr0NQd6M3LhXoMV8X5PK_K3UYfEPh02aLyE0oypVA
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+pharmacokinetic%2C+pharmacodynamic+and+drug-interaction+profile+of+the+integrase+inhibitor+dolutegravir&rft.jtitle=Clinical+pharmacokinetics&rft.au=Cottrell%2C+Mackenzie+L&rft.au=Hadzic%2C+Tanja&rft.au=Kashuba%2C+Angela+D+M&rft.date=2013-11-01&rft.issn=1179-1926&rft.eissn=1179-1926&rft.volume=52&rft.issue=11&rft.spage=981&rft_id=info:doi/10.1007%2Fs40262-013-0093-2&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0312-5963&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0312-5963&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0312-5963&client=summon